Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PRAN

Alterity Therapeutics (PRAN) Stock Price, News & Analysis

Alterity Therapeutics logo

About Alterity Therapeutics Stock (NASDAQ:PRAN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$2.87
$3.05
50-Day Range
$0.95
$2.06
52-Week Range
$1.09
$2.91
Volume
24,217 shs
Average Volume
130,956 shs
Market Capitalization
$26.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Remove Ads
Receive PRAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRAN Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Alterity Therapeutics Ltd PBN
Alterity Therapeutics to List New Securities on ASX
See More Headlines

PRAN Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include Meta Platforms (META), Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Intercept Pharmaceuticals (ICPT), Rigel Pharmaceuticals (RIGL), Arena Pharmaceuticals (ARNA) and Conatus Pharmaceuticals (CNAT).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRAN
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$150,000.00
Price / Cash Flow
N/A
Book Value
$1.40 per share
Price / Book
2.09

Miscellaneous

Free Float
N/A
Market Cap
$26.10 million
Optionable
Not Optionable
Beta
1.05
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:PRAN) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners